BNP/PUT/GILEAD SCIENCES/80/0.1/16.01.26 Stock

DE000PC1HZ18

Real-time Boerse Frankfurt Warrants 11:21:17 2024-07-03 am EDT
1.5 ^EUR	+4.90%

Current month	-1.38%
1 month	-15.88%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BNP/PUT/GILEAD SCIENCES/80/0.1/16.01.26

Latest news about GILEAD SCIENCES, INC.

HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	10:06am	AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	Jul. 01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	Jul. 01	CI
Gilead Benefit Helps Employees Navigate Cancer Care	Jul. 01	AQ

More news

Quotes 5-day view

Date	Price	Change
24-07-03	1.5	+4.90%
24-07-02	1.43	+0.70%
24-07-01	1.42	-2.07%
24-06-28	1.45	+2.11%
24-06-27	1.42	+2.16%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 11:21 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	GILEAD SCIENCES, INC.
Issuer	BNP Paribas
WKN	PC1HZ1
ISIN	DE000PC1HZ18
Date issued	2023-12-11
Strike	80 $
Maturity	2026-01-16 (562 Days)
Parity	10 : 1
Emission price	0.93 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.86 €
Lowest since issue	0.81 €
Spread	0.02 €
Spread %	1.30%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company